financetom
Business
financetom
/
Business
/
Lululemon Has Room for Earnings Beat-and-Raise, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lululemon Has Room for Earnings Beat-and-Raise, Morgan Stanley Says
Aug 29, 2024 2:00 AM

02:26 PM EDT, 08/26/2024 (MT Newswires) -- Lululemon Athletica ( LULU ) has the potential to deliver an earnings beat and a guidance raise in its upcoming results amid "lower-quality" drivers, though the company is likely to remain a "show-me" story in the near term, Morgan Stanley said in a note e-mailed Monday.

The athletic apparel and footwear company is scheduled to report its fiscal second-quarter results Thursday. Morgan Stanley projects earnings at $3 a share, compared with Wall Street's expectations for $2.94. Second Measure data indicate the company's US credit card sales likely fell 3% year over year in the quarter, following a 4% decline in the prior three-month period, the brokerage said in a note to clients.

"While not an inspiring result in aggregate, it suggests US trends have not necessarily gotten worse (quarter on quarter)," Morgan Stanley said. The firm expects China could represent revenue upside for Lululemon rather than a headwind. "Altogether, while (second-quarter) top-line results may not change the broader narrative, we think they can come in better than consensus forecasts."

The company's shares were up 1.7% in Monday afternoon trade.

For the ongoing quarter, the brokerage expects EPS of $2.83, above the Street's $2.71 estimate. For the full year, Morgan Stanley said the Street's $14.08 EPS outlook indicates the company could lower its guidance from its current range of $14.27 to $14.47. "Street EPS estimates suggest a (full-year) guidance cut is imminent, pointing to high skepticism in (management's) ability to correct recent inventory/innovation missteps (and) re-accelerate core market growth," the firm said. Morgan Stanley said it is looking for $14.37.

The Street expects downside to full-year guidance across various other metrics, including sales, with the underperformance seen concentrated in the second half of the year, according to the note. Morgan Stanley said it sees that outlook as "overly bearish" as the company likely has many tailwinds and levers in the period that it can pull to meet and/or surpass its current full-year guidance.

"While we admit that many of these EPS buffers would likely be perceived as lower-quality, (and) do little to debunk the bear thesis -- which hinges on Americas sales trends -- we nonetheless suspect they enable (full-year) EPS guidance to remain intact throughout the year, (and) perhaps even prove beat-able," the brokerage wrote.

Lululemon could increase its EPS guidance by $0.05 if it achieves second-quarter results in line with Morgan Stanley's expectations, according to the firm. "Unfortunately, even if (second-quarter) results come in better (and Lululemon) raises (full-year) EPS guidance, we suspect (Lululemon) will remain a 'show-me' story while its core (North America) market sales results remain challenged," the firm wrote. "This likely makes for a range-bound stock near-term."

Morgan Stanley lowered its price target on the Lululemon stock to $329 from $404 "on trimmed out-year sales expectations" while the brokerage reiterated its overweight rating. The company's "potentially compelling (second-half) rate-of-change-story, credible historical track record (and) still-attractive overall positioning" indicate the risk and reward skews to the upside from here, according to the note.

Price: 271.33, Change: +2.78, Percent Change: +1.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing
Apr 23, 2024
08:01 AM EDT, 04/23/2024 (MT Newswires) -- Adrian Haigh, CHIEF OPERATING OFFICER, around April 19, 2024, sold 44,445 shares in Fennec Pharmaceuticals ( FENC ) for $414,472. SEC Filing: https://www.sec.gov/Archives/edgar/data/1211583/000141588924011336/xslF345X03/form4-04222024_110404.xml ...
Freeport-McMoRan beats quarterly profit estimates
Freeport-McMoRan beats quarterly profit estimates
Apr 23, 2024
April 23 (Reuters) - Copper miner Freeport-McMoRan ( FCX ) beat Wall Street estimates for first-quarter profit on Tuesday, helped by higher production. On an adjusted basis, the Phoenix, Arizona-based company earned 32 cents per share for the three months ended March 31, compared with the average analyst estimate of 26 cents per share, according to LSEG data. (Reporting by...
UK's Pentair beats first-quarter profit estimates on price hikes
UK's Pentair beats first-quarter profit estimates on price hikes
Apr 23, 2024
April 23 (Reuters) - UK-based water technology company Pentair ( PNR ) reported better-than-expected quarterly profit on Tuesday, helped by the company's price hikes for its water purifiers. Pentair ( PNR ), which provides residential and industrial water technology products and services, had implemented price increases to offset slow demand for new pools and related services amid sticky inflation. Sales...
LKQ's Q1 Adjusted EPS Declines, Revenue Rises; Provides 2024 Guidance; Shares Drop 4% Pre-Bell
LKQ's Q1 Adjusted EPS Declines, Revenue Rises; Provides 2024 Guidance; Shares Drop 4% Pre-Bell
Apr 23, 2024
08:00 AM EDT, 04/23/2024 (MT Newswires) -- LKQ (LKQ) reported Q1 adjusted earnings Tuesday of $0.82 per diluted share, compared with $1.04 a year earlier. Analysts surveyed by Capital IQ expected $0.95. Revenue for the quarter ended March 31 was $3.70 billion, compared with $3.35 billion a year earlier. Analysts surveyed by Capital IQ expected $3.76 billion. For fiscal year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved